PARIS--(BUSINESS WIRE)--THERAVECTYS announced today a ruling by the Delaware Court of Chancery on the motion for preliminary injunction filed by THERAVECTYS against Immune Design Corp. (“IDC”) in a lawsuit filed in July 2014. THERAVECTYS alleges in its lawsuit that IDC tortiously interfered with its contractual rights by inducing Henogen SA (“Henogen”) to manufacture lentiviral vectors for IDC in breach of Henogen’s exclusive manufacturing obligations to THERAVECTYS, and that IDC also misappropriated THERAVECTYS’ trade secrets, among additional issues.
In its ruling, the Delaware Court held that THERAVECTYS is reasonably likely to succeed on the merits of its tortious interference claim, and also that “the record may later support a finding that [IDC’s conduct] constitutes trade secret misappropriation.” Although the Court declined to enter an injunction at this time, it expressly recognized that THERAVECTYS “may have claims for past damage” against IDC, and that “a final remedy tailored to address [IDC’s] conduct may [ultimately] be warranted.” The Court determined that, at this preliminary stage of the litigation, questions remain concerning the precise nature and degree of the additional harm THERAVECTYS would suffer prior to the trial, which is expected to be held later in 2015.
“We are very pleased and encouraged that the Court recognizes our likelihood of success in establishing IDC’s tortious interference with our contractual rights. We are optimistic about the outcome of our case at trial,” said THERAVECTYS CEO, Renaud VAILLANT.
THERAVECTYS is privately-owned, fully-integrated discovery and clinical development biotech company originating from the Pasteur Institute.
The company capitalizes over 15 years of fundamental research in the field of lentiviral vectors and has secured worldwide exclusive rights to Pasteur Institute intellectual property.
Based on its lentiviral vector technology platform, THERAVECTYS develops therapeutic
vaccines and immunotherapies to fight cancers and
infectious diseases, including a proprietary and differentiated
CAR T-cell technology platform.
The company is strongly supported by renowned investors and former global biopharmaceutical executives and is rapidly progressing in its R&D activities and in-house GMP production capabilities.
Alone and in collaboration with partners, THERAVECTYS is accelerating its clinical development programs and is planning to initiate two additional phase I/II clinical trials in oncology in 2015.